This case series study is the first report of Japanese adolescents who experienced dupilumab facial redness after starting dupilumab treatment for refractory atopic dermatitis. In every case, dupilumab facial redness subsided without discontinuation of dupilumab within 3 months after onset.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509969 | PMC |
| http://dx.doi.org/10.1016/j.jacig.2023.100096 | DOI Listing |
Publication Analysis
Top Keywords
facial redness
12
japanese adolescents
8
atopic dermatitis
8
dupilumab facial
8
dupilumab
5
redness japanese
4
adolescents atopic
4
dermatitis treated
4
treated dupilumab
4
dupilumab a case
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!